These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 19759892)

  • 1. A novel liposome-based adjuvant CAF01 for induction of CD8(+) cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice.
    Gram GJ; Karlsson I; Agger EM; Andersen P; Fomsgaard A
    PLoS One; 2009 Sep; 4(9):e6950. PubMed ID: 19759892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.
    Fomsgaard A; Karlsson I; Gram G; Schou C; Tang S; Bang P; Kromann I; Andersen P; Andreasen LV
    Vaccine; 2011 Sep; 29(40):7067-74. PubMed ID: 21767590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunity by formulation design: induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method.
    Nordly P; Rose F; Christensen D; Nielsen HM; Andersen P; Agger EM; Foged C
    J Control Release; 2011 Mar; 150(3):307-17. PubMed ID: 21111765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements.
    Agger EM; Rosenkrands I; Hansen J; Brahimi K; Vandahl BS; Aagaard C; Werninghaus K; Kirschning C; Lang R; Christensen D; Theisen M; Follmann F; Andersen P
    PLoS One; 2008 Sep; 3(9):e3116. PubMed ID: 18776936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.
    Schmidt ST; Olsen CL; Franzyk H; Wørzner K; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
    Eur J Pharm Biopharm; 2019 Jul; 140():29-39. PubMed ID: 31055066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses.
    Oseroff C; Sette A; Wentworth P; Celis E; Maewal A; Dahlberg C; Fikes J; Kubo RT; Chesnut RW; Grey HM; Alexander J
    Vaccine; 1998 May; 16(8):823-33. PubMed ID: 9627940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant.
    Korsholm KS; Hansen J; Karlsen K; Filskov J; Mikkelsen M; Lindenstrøm T; Schmidt ST; Andersen P; Christensen D
    Vaccine; 2014 Jun; 32(31):3927-35. PubMed ID: 24877765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopes.
    Corbet S; Nielsen HV; Vinner L; Lauemoller S; Therrien D; Tang S; Kronborg G; Mathiesen L; Chaplin P; Brunak S; Buus S; Fomsgaard A
    J Gen Virol; 2003 Sep; 84(Pt 9):2409-2421. PubMed ID: 12917462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses.
    Davidsen J; Rosenkrands I; Christensen D; Vangala A; Kirby D; Perrie Y; Agger EM; Andersen P
    Biochim Biophys Acta; 2005 Dec; 1718(1-2):22-31. PubMed ID: 16321607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small cationic DDA:TDB liposomes as protein vaccine adjuvants obviate the need for TLR agonists in inducing cellular and humoral responses.
    Milicic A; Kaur R; Reyes-Sandoval A; Tang CK; Honeycutt J; Perrie Y; Hill AV
    PLoS One; 2012; 7(3):e34255. PubMed ID: 22470545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity.
    Bijker MS; van den Eeden SJ; Franken KL; Melief CJ; Offringa R; van der Burg SH
    J Immunol; 2007 Oct; 179(8):5033-40. PubMed ID: 17911588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Mycobacterium tuberculosis CTL epitopes restricted by HLA-A*0201 in HHD mice.
    Rafiei A; Kiutade Y
    Iran Biomed J; 2007 Jan; 11(1):23-31. PubMed ID: 18051701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01.
    Ingvarsson PT; Schmidt ST; Christensen D; Larsen NB; Hinrichs WL; Andersen P; Rantanen J; Nielsen HM; Yang M; Foged C
    J Control Release; 2013 May; 167(3):256-64. PubMed ID: 23415813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
    Wilkinson A; Lattmann E; Roces CB; Pedersen GK; Christensen D; Perrie Y
    J Control Release; 2018 Dec; 291():1-10. PubMed ID: 30291987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adsorption of protein antigen to the cationic liposome adjuvant CAF®01 is required for induction of Th1 and Th17 responses but not for antibody induction.
    Wørzner K; Hvannastein J; Schmidt ST; Foged C; Rosenkrands I; Pedersen GK; Christensen D
    Eur J Pharm Biopharm; 2021 Aug; 165():293-305. PubMed ID: 34044110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE.
    Miyahara Y; Naota H; Wang L; Hiasa A; Goto M; Watanabe M; Kitano S; Okumura S; Takemitsu T; Yuta A; Majima Y; Lemonnier FA; Boon T; Shiku H
    Clin Cancer Res; 2005 Aug; 11(15):5581-9. PubMed ID: 16061876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation.
    Schumacher R; Adamina M; Zurbriggen R; Bolli M; Padovan E; Zajac P; Heberer M; Spagnoli GC
    Vaccine; 2004 Jan; 22(5-6):714-23. PubMed ID: 14741164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1.
    Wilson CC; McKinney D; Anders M; MaWhinney S; Forster J; Crimi C; Southwood S; Sette A; Chesnut R; Newman MJ; Livingston BD
    J Immunol; 2003 Nov; 171(10):5611-23. PubMed ID: 14607970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary Administration of the Liposome-Based Adjuvant CAF01: Effect of Surface Charge on Mucosal Adjuvant Function.
    Müllertz OAO; Andersen P; Christensen D; Foged C; Thakur A
    Mol Pharm; 2023 Feb; 20(2):953-970. PubMed ID: 36583936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequence conservation of subdominant HLA-A2-binding CTL epitopes in HIV-1 clinical isolates and CD8+ T-lymphocyte cross-recognition may explain the immune reaction in infected individuals.
    Thorn M; Tang S; Therrien D; Kløverpris H; Vinner L; Kronborg G; Gerstoft J; Corbet S; Fomsgaard A
    APMIS; 2007 Jun; 115(6):757-68. PubMed ID: 17550385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.